However, significant protection against microscopic neoplastic lesions was only achieved when anti-Her2 vaccination was associated with protocols that contrast tumor-induced immune suppression, such as T regulatory cell depletion [13,49], or when vaccination was directed against the tumor vasculature, as in vaccination against angiomotin, which is one of the angiostatin receptors expressed by endothelial cells in BALB-neuT tumors [50]. This evidence concerns the gene ERBB2 and neoplasm.